Nomura Shiho, Nozaki Satoshi, Hamazaki Takashi, Takeda Taisuke, Ninomiya Eiichi, Kudo Satoshi, Hayashinaka Emi, Wada Yasuhiro, Hiroki Tomoko, Fujisawa Chie, Kodama Hiroko, Shintaku Haruo, Watanabe Yasuyoshi
Department of Pediatrics, Graduate School of Medicine, Osaka City University, Osaka, Japan.
J Nucl Med. 2014 May;55(5):845-51. doi: 10.2967/jnumed.113.131797. Epub 2014 Mar 13.
Menkes disease (MD), an X-linked recessive disorder of copper metabolism caused by mutations in the copper-transporting ATP7A gene, results in growth failure and severe neurodegeneration in early childhood. Subcutaneous copper-histidine injection is the standard treatment for MD, but it has limited clinical efficacy. Furthermore, long-term copper injection causes excess copper accumulation in the kidneys, resulting in renal dysfunction. To attempt to resolve this issue, we used PET imaging with (64)Cu to investigate the effects of disulfiram on copper biodistribution in living mice serving as an animal model for MD (MD model mice).
Macular mice were used as MD model mice, and C3H/He mice were used as wild-type mice. Mice were pretreated with 2 types of chelators (disulfiram, a lipophilic chelator, and d-penicillamine, a hydrophilic chelator) 30 min before (64)CuCl2 injection. After (64)CuCl2 injection, emission scans covering the whole body were performed for 4 h. After the PET scans, the brain and kidneys were analyzed for radioactivity with γ counting and autoradiography.
After copper injection alone, marked accumulation of radioactivity ((64)Cu) in the liver was demonstrated in wild-type mice, whereas in MD model mice, copper was preferentially accumulated in the kidneys (25.56 ± 3.01 percentage injected dose per gram [%ID/g]) and was detected to a lesser extent in the liver (13.83 ± 0.26 %ID/g) and brain (0.96 ± 0.08 %ID/g). Copper injection with disulfiram reduced excess copper accumulation in the kidneys (14.54 ± 2.68 %ID/g) and increased copper transport into the liver (29.42 ± 0.98 %ID/g) and brain (5.12 ± 0.95 %ID/g) of MD model mice. Copper injection with d-penicillamine enhanced urinary copper excretion and reduced copper accumulation in most organs in both mouse groups. Autoradiography demonstrated that disulfiram pretreatment induced copper transport into the brain parenchyma and reduced copper accumulation in the renal medulla.
PET studies with (64)Cu revealed that disulfiram had significant effects on the copper biodistribution of MD. Disulfiram increased copper transport into the brain and reduced copper uptake in the kidneys of MD model mice. The application of (64)Cu PET for the treatment of MD and other copper-related disorders may be useful in clinical settings.
门克斯病(MD)是一种由铜转运ATP7A基因突变引起的X连锁隐性铜代谢障碍疾病,导致幼儿期生长发育迟缓及严重的神经退行性变。皮下注射铜组氨酸是MD的标准治疗方法,但临床疗效有限。此外,长期注射铜会导致肾脏中铜过量蓄积,进而引起肾功能障碍。为解决这一问题,我们使用(64)Cu正电子发射断层显像(PET)来研究双硫仑对作为MD动物模型(MD模型小鼠)的活体小鼠铜生物分布的影响。
将黄斑小鼠用作MD模型小鼠,C3H/He小鼠用作野生型小鼠。在注射(64)CuCl2前30分钟,用两种螯合剂(双硫仑,一种亲脂性螯合剂;d-青霉胺,一种亲水性螯合剂)对小鼠进行预处理。注射(64)CuCl2后,进行4小时的全身发射扫描。PET扫描后,用γ计数和放射自显影分析脑和肾脏的放射性。
单独注射铜后,野生型小鼠肝脏中显示出明显的放射性((64)Cu)蓄积,而在MD模型小鼠中,铜优先蓄积在肾脏(25.56±3.01每克注射剂量百分比[%ID/g]),在肝脏(13.83±0.26 %ID/g)和脑(0.96±0.08 %ID/g)中检测到的程度较低。双硫仑联合注射铜可减少MD模型小鼠肾脏中过量的铜蓄积(14.54±2.68 %ID/g),并增加铜向肝脏(29.42±0.98 %ID/g)和脑(5.12±0.95 %ID/g)的转运。d-青霉胺联合注射铜可增强两组小鼠的尿铜排泄,并减少大多数器官中的铜蓄积。放射自显影显示,双硫仑预处理可诱导铜转运至脑实质,并减少肾髓质中的铜蓄积。
(64)Cu PET研究表明,双硫仑对MD的铜生物分布有显著影响。双硫仑增加了MD模型小鼠脑内的铜转运,并减少了肾脏对铜的摄取。(64)Cu PET在MD及其他与铜相关疾病治疗中的应用可能在临床环境中具有实用性。